特刊:"凝的合成,表征和制药应用"
1School of Health and Life Sciences, University of Teesside, Middlesborough TS1 3BX, UK.
Gels (Basel, Switzerland)
|February 26, 2026
概括
凝合成和配方技术的进步正在为制药使用创造新的凝系统. 这些创新在药物输送和医疗治疗中提供了多样化的应用.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 生物技术是生物技术.
背景情况:
- 凝合成和配方技术一直在不断进步.
- 对这些技术的理解有了显著的改善.
- 这导致了新的凝系统的开发.
研究的目的:
- 探索新凝系统的多样化药物应用.
- 突出技术进步对基于凝的药物输送的影响.
- 讨论新的凝配方在医学中的潜力.
主要方法:
- 关于凝合成和配方的最新文献的综述.
- 分析新型凝系统及其特性.
- 药物应用的案例研究.
主要成果:
- 新型凝系统具有独特的特性,适合药物输送.
- 在控制释放和组织工程等领域发现了多种不同的应用.
- 技术的改进使得量身定制的凝配方变得更加容易.
结论:
- 先进的凝技术对于开发下一代制药产品至关重要.
- 新型凝系统为改善治疗结果提供了巨大的潜力.
- 凝科学领域的持续研究将推动制药创新.
相关概念视频
Drug Concentrations: Measurements
1.6K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
1.6K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Pharmaceutical Equivalents
274
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
274
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Production of Pharmaceuticals
94
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
94


